Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio

Organon & Co.

Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.
Dermavant shareholders also earn tiered royalty payments based on VTAMA net sales.
Transaction expected to close Q4 2024, subject to HSR and other customary conditions.
VTAMA (tapinarof) is approved for plaque psoriasis; milestone targets atopic dermatitis indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.